Author profile
Department of Oncology, Western University
To accurately calculate the cellular-level absorbed dose for 225Ac, 177Lu, and 161Tb radioligand therapy (RLT), accounting for tumor microstructure, self-irradiation, crossfire, and bystander effects.
We introduce a framework to optimize administered radioligand activity by calculating DNA lethal lesions (LLs), balancing maximal tumor control with minimal normal tissue damage.
Accurately identifying clinically significant prostate cancer (PCa) lesions remains a difficult task. Although tumor characteristics associated with false-negative lesions have been investigated, the potential radiologist search strategy issues underlying mis...
Two key challenges in pharmacokinetic modeling (PKM) of dynamic PET are metabolite contamination of the image-derived arterial input function (AIF) and the presence of these metabolites in tissue time-activity curves (TACs). We propose a method to correct for...